Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

A total of 1636 ALS incident subjects were detected in the three regions, mainly aged 65-74 years. Patients were generally fragile with a high prevalence of comorbidities at baseline. Riluzole was used by 27.4% of the overall study cohort at baseline and steeply increased in the first year after the index date differently between regions (Latium 61.2%, Tuscany 85.0%, Umbria 76.5%), with about half of the subjects being incident users. In the 12 months after the index date, also symptomatic therapies increased, in riluzole users and non-users. Determinants analysis showed that higher patient severity and complexity were associated with a lower likelihood of being treated with riluzole.

Authors

Institutions

Publication Details

Journal
European Journal of Neurology
Published
2024-09-19
DOI
https://doi.org/10.1111/ene.16470
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

Olga Paoletti, Antonio Addis, Ursula Kirchmayer, Maria Grazia Celani et al.
European Journal of Neurology
Amyotrophic Lateral Sclerosis Research
article

Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

Olga Paoletti, Antonio Addis, Ursula Kirchmayer, Maria Grazia Celani, Giada Crescioli, Giulia Hyeraci, Silvia Cascini, Niccolò Lombardi, Rosa Gini, Ilaria Bacigalupo, Marco Finochietti, Marco Tuccori
article en

Abstract

A total of 1636 ALS incident subjects were detected in the three regions, mainly aged 65-74 years. Patients were generally fragile with a high prevalence of comorbidities at baseline. Riluzole was used by 27.4% of the overall study cohort at baseline and steeply increased in the first year after the index date differently between regions (Latium 61.2%, Tuscany 85.0%, Umbria 76.5%), with about half of the subjects being incident users. In the 12 months after the index date, also symptomatic therapies increased, in riluzole users and non-users. Determinants analysis showed that higher patient severity and complexity were associated with a lower likelihood of being treated with riluzole.

European Journal of NeurologyVol. 31(12)
University of Pisa (IT), Istituto Superiore di Sanità (IT), Azienda Ospedaliera di Perugia (IT), ASL Roma (IT), National Centre for Disease Prevention and Control (IT), Agenzia Regionale di Sanità della Toscana (IT), University of Florence (IT)
Università degli Studi di Firenze, Università di Pisa, Agenzia Italiana del Farmaco, Ministero della Salute
Openalex Percentile: Top 75%
Amyotrophic Lateral Sclerosis Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.